Last $13.30 USD
Change Today -0.06 / -0.45%
Volume 33.0K
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

veracyte inc (VCYT) Snapshot

Open
$13.36
Previous Close
$13.36
Day High
$13.46
Day Low
$13.25
52 Week High
03/19/14 - $19.00
52 Week Low
11/7/13 - $10.88
Market Cap
281.5M
Average Volume 10 Days
57.4K
EPS TTM
--
Shares Outstanding
21.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERACYTE INC (VCYT)

Related News

No related news articles were found.

veracyte inc (VCYT) Related Businessweek News

No Related Businessweek News Found

veracyte inc (VCYT) Details

Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignancy Classifiers for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

115 Employees
Last Reported Date: 03/20/14
Founded in 2006

veracyte inc (VCYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $380.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $201.0K
Chief Commercial Officer
Total Annual Compensation: $316.3K
Compensation as of Fiscal Year 2013.

veracyte inc (VCYT) Key Developments

Veracyte, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Revenue Guidance for the Year 2014

Veracyte, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported revenue of $6.8 million, an increase of 53%, compared to 2012 fourth quarter revenue of $4.5 million. Net loss was $5.9 million, or $0.42 per common share, compared with a net loss of $4.8 million, or $7.27 per common share, for the same period in 2012. Loss from operations was $5.762 million against $5.116 million a year ago. Full-year 2013, the company's revenue was $21.9 million, an increase of 88%, compared to full-year 2012 revenue of $11.6 million. Net loss was $25.6 million, or $6.15 per common share, compared with a net loss of $18.6 million, or $28.68 per common share, for 2012. Loss from operations was $23.173 million against $18.929 million a year ago. For the year 2014, the company expects revenue to be in the range of $38 million to $43 million.

Veracyte, Inc. Announces the Appointments of Two Executives to its Management Team

Veracyte, Inc. announced the appointments of two executives to its management team. Julie A. Brooks joins the company as executive vice president, general counsel and secretary; and Andy Thorson joins as executive vice president, corporate strategy and business development. Ms. Brooks brings over 23 years of experience as a general counsel and executive team member, primarily for publicly-held and venture-backed global medical device, biotechnology and healthcare IT companies. Most recently, she served as EVP, general counsel and secretary for Conceptus, Inc. Mr. Thorson has more than 20 years of experience in senior business development and finance roles for start-up, publicly held and multi-national companies. He served as corporate vice president, finance & business development at Varian Medical Systems, Inc.

Veracyte, Inc., Q4 2013 Earnings Call, Mar 18, 2014

Veracyte, Inc., Q4 2013 Earnings Call, Mar 18, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCYT:US $13.30 USD -0.06

VCYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Laboratory Corp of America Holdings $101.31 USD -0.64
Quest Diagnostics Inc $59.48 USD -0.50
View Industry Companies
 

Industry Analysis

VCYT

Industry Average

Valuation VCYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.5x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERACYTE INC, please visit www.veracyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.